MC10 and global biopharmaceutical company UCB have entered into a partnership to develop MC10’s Biostamp platform for patient-focused disease management solutions. The collaboration will test out the integration of MC10’s conformal sensing platform with UCB’s pharmaceutical products to make a positive difference in the lives of people living with severe neurological disorders.

MC10’s stretchable, electronic sensing systems can bend, flex and twist to match the properties of the human body.MC10’s stretchable, electronic sensing systems can bend, flex and twist to match the properties of the human body. The accompanying Biostamp platform offers a patient-friendly solution for disease monitoring and management. This passive monitoring of patient health data will not only help patients but also doctors to provide more personalized care. Moreover, it could help to accelerate neuroscience clinical research and provide insight into the real world impact of therapies.

“Wearable technology has the power to transform the way healthcare is both received and delivered,” said Ben Schlatka, Co-Founder and VP of Corporate Development at MC10. “UCB’s patient-centric approach to medicine was a great fit with MC10’s human-centric approach to wearable technology design.”